@BiVictriXTherapeutics

These compelling results demonstrate the potential of BVX002 to deliver meaningful efficacy where other B7-H4-targeted ADCs fall short. To read more about this study, visit our website.

In a mouse unresponsive to AstraZeneca’s B7H4-TOPOi-based ADC, AZD8205, a single dose of BVX002 was not only able to reverse the exponential growth of the tumour but also resulted in tumour regressions of >62% in just 14 days!

🚀 Exciting news from BiVictriX! Our lead solid‑tumour ADC, BVX002, has delivered tumour growth inhibition and regressions in an AZD8205-resistant mouse 🎯 New data shows that a single dose of BVX002 reverses tumour growth in an AZD8205-resistant mouse 🌟

🔗 Read the full press release for the data & context: lnkd.in/evbRu9Fa #Oncology #Biotech #PharmaInnovation #BispecificADC

✅ Our Bi-Cygni® platform breaks through expression thresholds that limit conventional ADCs. 🧬 Precision, potency, and consistent DAR4 from our site-specific conjugation tech. We’re setting a new bar in #ADC innovation.

🚀 Preclinical win for #BiVictriX: Our bispecific ADC, BVX002, outperformed 2 B7H4-targeted competitors (Pfizer’s SGN-B7H4V* & AZ’s AZD8205*) in head-to-head studies. 📊 Tumor regressions across all doses tested. 👇 More on why this matters:

🔬 At BiVictriX, we’re not confined to 1 ADC design philosophy. Our BVX002 programme employs an innovative “AND/OR”-gated bispecific ADC to tackle ovarian cancer's tumour heterogeneity. It’s about clinically relevant solutions, not just being different. #ADC #bispecific #oncology

We’ve got MORE exciting data to share with you! 🚨 Our latest pre-clinical study found that BVX001 increased survival rates in acute myeloid leukaemia (AML) by 126% compared to an untreated control group. Find out more: bivictrix.com/news/extended-… #AML #BloodCancer #antibodies

$BVX Bivictrix Therapeutics progress attracting interest, says CEO tinyurl.com/22q2gvfu @bivictrix $BVTXF #BVX #BVTXF

We're pleased to announce our lead asset, BVX001, has been granted a US patent! This is a big step on BiVictriX's journey, providing broad protection for our lead therapeutic asset at the antigen level. Find out more: bivictrix.com/news/us-patent… #bloodcancer #AML #ADC #biotech

Is the accepted dogma around the therapeutic window of #ADCs in need of a rethink? In their recent paper, Columbo and Rich highlight the mounting clinical evidence that suggests ADCs do not significantly increase the MTD of their conjugated drugs: cell.com/cancer-cell/pd…

Discover how our clinical lead candidate, BVX001, addresses some of the shortcomings of current antibody drug conjugate (ADC) treatments for acute myeloid leukaemia in this in-depth article in @Labiotech_eu labiotech.eu/in-depth/bivic… #ADC #AML #pipeline #biotech

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine - zurl.co/ai4z

$BVX BiVictriX sees positive final data in BVX001 leukaemia drug study tinyurl.com/2kuo5gml @bivictrix $BVTXF #BVX #BVTXF

We’re delighted to share positive final data in the preclinical efficacy study of BVX001, our lead Bi-Cygni® bi-specific ADC for AML. Find out more: linkedin.com/feed/update/ur… #ADC #AML #pipeline #Drugdevelopment

With Cancer Immunotherapy Month coming to an end, we wanted to highlight another way we are contributing to the development of high-impact cancer therapies. Discover more about our science and pipeline: linkedin.com/feed/update/ur… #CIM23 #Immune2Cancer #immunotherapy

We’re excited to reveal the positive interim data from our second preclinical efficacy study of BVX001 — our lead ADC programme for AML - in larger tumours. Read more: bivictrix.com/news/positive-… #ADC #AML #Biotech #pipeline #antibodytherapeutics #oncology #drugdevelopment

$BVX BiVictriX Therapeutics data underscores the potential of leukemia drug tinyurl.com/23lbj668 @bivictrix $BVTXF #BVX #BVTXF

$BVX BiVictriX Therapeutics shares close 7% higher after making preclinical progress tinyurl.com/2n9za589 @bivictrix $BVTXF #BVX #BVTXF